| Literature DB >> 29636075 |
Jiali Shao1, Jian Wang1, Jiangju Huang1, Chang Liu1, Yundan Pan1, Qulian Guo1, Wangyuan Zou2.
Abstract
Morphine tolerance is a challenging clinical problem that limits the use of morphine in pain treatment, but the mechanisms of morphine tolerance remain unclear. Recent research indicates that long noncoding RNAs (lncRNAs) might be a novel and promising target in the pathogeneses of diseases. Therefore, we hypothesized that lncRNAs might play a role in the development of morphine tolerance. Male Sprague-Dawley rats were intrathecally injected with 10 μg morphine twice daily for 7 consecutive days. The animals were then sacrificed for lncRNA microarray tests, and the results were validated by RT-qPCR. Next, functional predictions for the differentially expressed mRNAs (DEmRNAs) were made with the Gene Ontology/Kyoto Encyclopedia of Genes and Genomes (GO/KEGG), and predictions for the differentially expressed lncRNAs (DElncRNAs) were made based on competitive endogenous RNA (ceRNA) analyses. The rats successfully developed morphine tolerance. LncRNA microarray analysis revealed that, according to the criteria of a log2 (fold change) > 1.5 and a P-value < 0.05, 136 lncRNAs and 278 mRNAs were differentially expressed in the morphine tolerance group (MT) compared with the normal saline group (NS). The functions of the DEmRNAs likely involve in the processes of the ion channel transport, pain transmission and immune response. The ceRNA analysis indicated that several possible interacting networks existed, including (MRAK150340, MRAK161211)/miR-219b/Tollip.Further annotations of the potential target mRNAs of the miRNAs according to the gene database suggested that the possible functions of these mRNAs primarily involved the regulation of ubiquitylation, G protein-linked receptors, and Toll-like receptors, which play roles in the development of morphine tolerance. Our findings revealed the profiles of differentially expressed lncRNAs in morphine tolerance conditions, and among these lncRNAs, some DElncRNAs might be new therapeutic targets for morphine tolerance.Entities:
Keywords: LncRNA; Morphine tolerance; Spinal cord; ceRNA
Mesh:
Substances:
Year: 2018 PMID: 29636075 PMCID: PMC5894177 DOI: 10.1186/s13041-018-0365-8
Source DB: PubMed Journal: Mol Brain ISSN: 1756-6606 Impact factor: 4.041
The detailed information of primer sequence
| Sequence name | Primer sequence | Amplicon size (bp) |
|---|---|---|
| GAPDH(RAT) | F:5’ GCTCTCTGCTCCTCCCTGTTCTA3’ | 124 |
| MRAK161211 | F:5’CTGACCCCAAAGTTTCACATCT3’ | 63 |
| MRAK038897 | F:5’TGGCAAGAATACCAAAGAGC3’ | 132 |
| MRAK014088 | F:5’GTGTCTATTTCTGGGAGTCTGTGC3’ | 102 |
| MRAK080737 | F:5’GTGCCAGACCCCAAGGTAAA3’ | 105 |
| MRAK159688 | F:5’GTACTGTAGCTCTTCAGCGTCC3’ | 78 |
| MRAK046606 | F:5’GCCAGCATCTCCTACTCACA3’ | 80 |
| MRAK150340 | F:5’ACAGAGTAGGGCAGTCGCAG3’ | 205 |
| DQ266361 | F:5’TGTGGTTAAATCCCCATGC3’ | 63 |
| XR_006440 | F:5’GGAGCATCAAATCGAAAGC3’ | 162 |
| XR_005988 | F:5’TGTGACACCACTGAGACCCTT3’ | 101 |
| uc.48+ | F:5’ AAATGCAAACTGGATGAGGA 3′ | 279 |
| uc.310- | F:5’ CTAATCAAAAACTGACAGCAAGA 3′ | 128 |
| XR_009527 | F:5’ CCAAGGCCCGTATTGAGATTA 3′ | 116 |
| XR_008662 | F:5’ TAATGAGGAAGATGAGAATGGC 3′ | 103 |
| S66184 | F:5’ TCTTCACATTACCATTACGAGGA 3′ | 51 |
| AF196267 | F:5’ GCCATCAATTTTCTCTTGACTG 3′ | 135 |
| MRAK077287 | F:5’ GCTAATAATTCCTACCAGCAAA 3′ | 151 |
| MRAK141001 | F:5’ CTTCCCTACCAGTCTATTGAGTG 3′ | 87 |
| S100a8 | F:5’GGGAATCACCATGCCCTCTA3′ | 168 |
| Batf | F:5’GAGGACCTGGAGAAACAGAATG3’ | 87 |
| Ccl7 | F:5’GCTGCTATGTCAAGAAACAAAAGA3’ | 136 |
| RT1-Bb | F:5’GCCCTCAACCACCACAACTT3’ | 141 |
| Prrx2 | F:5’AAGAAGAAGCAGCGTCGGA3’ | 97 |
| Asb2 | F:5’TGCTTTTCCTGCCTGTATGG3’ | 120 |
| RatNP-3b | F:5’ CATACGCCAAAGTCTGAAACC 3′ | 168 |
| Grm2 | F:5’ CCCGGAGAACTTCAACGAA 3′ | 207 |
| Mmp9 | F:5’ CCCACTTACTTTGGAAACG 3′ | 228 |
| Fam111a | F:5’ GACTATTTCTCTCAGGTTCCCA 3′ | 256 |
| Kcnv2 | F:5’ GGGCTGCGGTAAGCATCTCT 3′ | 106 |
| Tmem119 | F:5’ AGACAGTCGAACGGTCTAACAG 3′ | 127 |
Fig. 1(a) Continuous injection of morphine for 7 days induced the formation of morphine analgesic tolerance. The data are expressed as the mean ± s.e.m. (n = 8 in each group). **P < 0.01, ***P < 0.001, Two-way repeated-measures of ANOVA followed by Bonferroni test. Ten samples (n = 5 in each group) were subjected to microarray analysis. b-c The entire and partial hierarchical clusterings of the lncRNAs and mRNAs, respectively; the up- and down-regulated genes are colored in red and green, respectively. d Scatter plot displaying the lncRNAs and mRNAs that exhibited expression differences between the MT and NS groups that exceeded 1.5-fold
The detailed information of top 40 up-regulated and 40 down-regulated lncRNAs
| Up-regulated lncRNAs | Fold change(MT/NS) | P-value | Down-regulated lncRNAs | Fold change(MT/NS) | |
|---|---|---|---|---|---|
| XR_005988 | 12.34156 | 0.003685 | AF196267 | 2.202529 | 0.012181 |
| DQ266361 | 2.486278 | 0.000882 | XR_009493 | 2.115125 | 0.019025 |
| MRAK046606 | 2.367485 | 0.020344 | MRAK150340 | 2.060765 | 0.000308 |
| uc.167- | 2.199281 | 0.002987 | MRAK037188 | 1.956905 | 0.000066 |
| uc.468+ | 2.137996 | 0.000249 | XR_006440 | 1.952104 | 0.003301 |
| XR_009482 | 2.065426 | 0.022224 | AF196206 | 1.938910 | 0.015500 |
| AF305713 | 2.052460 | 0.001121 | BC126091 | 1.906750 | 0.020304 |
| MRAK165072 | 2.020835 | 0.015095 | uc.370+ | 1.900405 | 0.000477 |
| MRAK159688 | 2.009110 | 0.008496 | MRAK156916 | 1.879795 | 0.013478 |
| uc.28- | 1.957873 | 0.033513 | XR_008800 | 1.872603 | 0.022847 |
| DQ223059 | 1.911577 | 0.043779 | MRAK077287 | 1.816863 | 0.000017 |
| uc.48+ | 1.897821 | 0.005311 | MRAK014088 | 1.773360 | 0.000324 |
| XR_006726 | 1.887222 | 0.008923 | MRAK161211 | 1.765669 | 0.014718 |
| XR_009483 | 1.883845 | 0.020077 | BC158785 | 1.742858 | 0.005583 |
| MRAK013672 | 1.849562 | 0.027735 | MRuc009dux | 1.721422 | 0.014515 |
| MRAK018927 | 1.848401 | 0.025469 | MRAK135122 | 1.718807 | 0.009117 |
| uc.482- | 1.827252 | 0.000618 | MRAK141001 | 1.690469 | 0.000352 |
| MRAK138235 | 1.824250 | 0.005928 | MRuc007nwi | 1.688666 | 0.043028 |
| uc.156- | 1.810205 | 0.037932 | uc.264- | 1.687839 | 0.023742 |
| XR_008353 | 1.802395 | 0.008201 | EF088428 | 1.673345 | 0.001656 |
| uc.462+ | 1.791152 | 0.001958 | uc.363+ | 1.672870 | 0.011181 |
| MRAK134839 | 1.770980 | 0.033987 | BC169026 | 1.665411 | 0.007442 |
| MRAK054291 | 1.760502 | 0.037076 | MRAK008891 | 1.659204 | 0.018204 |
| BC093392 | 1.758918 | 0.030404 | MRAK135686 | 1.656007 | 0.005067 |
| MRuc007cgx | 1.756746 | 0.023148 | MRAK051195 | 1.625373 | 0.000267 |
| MRAK050995 | 1.742487 | 0.032134 | BC097960 | 1.619298 | 0.003837 |
| XR_009527 | 1.742256 | 0.022408 | MRAK169397 | 1.617138 | 0.030259 |
| uc.395- | 1.733383 | 0.035051 | MRAK046121 | 1.614043 | 0.005023 |
| XR_005532 | 1.732123 | 0.042440 | MRAK080238 | 1.594013 | 0.000840 |
| uc.158- | 1.723747 | 0.010144 | BC061963 | 1.592978 | 0.002208 |
| MRuc007jeg | 1.722591 | 0.006501 | MRAK013677 | 1.592863 | 0.000261 |
| XR_008662 | 1.716865 | 0.020951 | XR_009137 | 1.575140 | 0.014863 |
| XR_008674 | 1.695926 | 0.047672 | BC086373 | 1.561696 | 0.008523 |
| S66184 | 1.680145 | 0.026505 | MRAK083715 | 1.557152 | 0.004611 |
| M81783 | 1.670161 | 0.011349 | MRAK038897 | 1.555085 | 0.007252 |
| MRAK083472 | 1.662885 | 0.008172 | MRAK041309 | 1.554516 | 0.000067 |
| XR_009489 | 1.660491 | 0.002298 | MRAK147844 | 1.551990 | 0.000730 |
| XR_008266 | 1.654757 | 0.012200 | MRAK051810 | 1.549681 | 0.022164 |
| uc.310- | 1.653784 | 0.013204 | uc.185+ | 1.545991 | 0.024361 |
| uc.463- | 1.651362 | 0.021613 | BC079474 | 1.544677 | 0.000147 |
The detailed information of top 30 up-regulated and 30 down-regulated mRNAs
| Gene symbol | Description | Fold change(MT/NS) | |
|---|---|---|---|
| Up-regulated genes | |||
| RT1-Bb | RT1 class II, locus Bb | 26.0600137 | 0.03123893 |
| RatNP-3b | defensin RatNP-3 precursor | 4.6945682 | 0.00237615 |
| Lilrb3 | leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3 | 4.3359795 | 0.00815228 |
| Defa7 | alpha-defensin 7 | 4.2552547 | 0.00156229 |
| Clecsf9 | macrophage-inducible C-type lectin | 3.4622832 | 0.01864872 |
| Ccl7 | chemokine (C-C motif) ligand 7 | 3.3728046 | 0.01483951 |
| Sele | selectin, endothelial cell | 3.3632425 | 0.03028204 |
| Slpi | secretory leukocyte peptidase inhibitor | 3.2118152 | 0.00024306 |
| Lilrc2 | leukocyte immunoglobulin-like receptor | 3.1471364 | 0.01375120 |
| V1rj4 | vomeronasal 1 receptor, J4 | 2.9047312 | 0.03220865 |
| Gja5 | gap junction membrane channel protein alpha 5 | 2.8707048 | 0.02230140 |
| Mmp9 | matrix metallopeptidase 9 | 2.832538 | 0.02991875 |
| Batf | basic leucine zipper transcription factor | 2.7432184 | 0.00125327 |
| S100a8 | S100 calcium binding protein A8 (calgranulin A) | 2.7009035 | 0.00561932 |
| Birc3 | baculoviral IAP repeat-containing 3 | 2.6968995 | 0.01058921 |
| Bcl3 | B-cell CLL/lymphoma 3 | 2.6847827 | 0.00419171 |
| Ccr1 | chemokine (C-C motif) receptor 1 | 2.5775393 | 0.00007731 |
| Olr463 | olfactory receptor 463 (predicted) | 2.5772986 | 0.01425058 |
| Np4 | defensin NP-4 precursor | 2.4883044 | 0.00271115 |
| Grm2 | glutamate receptor, metabotropic 2 | 2.4429944 | 0.00113554 |
| Slpil2 | antileukoproteinase-like 2 | 2.4380328 | 0.00066484 |
| Cnn1 | calponin 1 | 2.4269788 | 0.02918954 |
| Olr139 | olfactory receptor Olr139 | 2.4268332 | 0.01332394 |
| Obp3 | alpha-2u globulin PGCL4 | 2.3723118 | 0.03995990 |
| Crisp4 | cysteine-rich secretory protein 4 | 2.3633549 | 0.00810051 |
| Olr1454_predicted | olfactory receptor 1454 (predicted) | 2.3350625 | 0.00247670 |
| Napsa | napsin A aspartic peptidase | 2.2770041 | 0.00035275 |
| Olr1374_predicted | olfactory receptor 1374 (predicted) | 2.2313479 | 0.00040213 |
| LOC497796 | Ly49 inhibitory receptor-like | 2.2302475 | 0.00022859 |
| Slpil3 | antileukoproteinase-like 3 | 2.2153032 | 0.00045886 |
| Down-regulated genes | |||
| Fam111a | hypothetical protein LOC499322 | 5.1287218 | 0.02433528 |
| Kcnv2 | “potassium channel, subfamily V, member 2” | 2.8837136 | 0.00586212 |
| Fkbp6 | FK506 binding protein 6 | 2.8648794 | 0.00576975 |
| Nlrp10 | “NLR family, pyrin domain containing 10” | 2.6101210 | 0.00386452 |
| Rgs1 | regulator of G-protein signaling 1 | 2.4933037 | 0.00327101 |
| Ly49i8 | Ly49 inhibitory receptor 8 | 2.3732515 | 0.01051908 |
| Tmem119 | transmembrane protein 119 | 2.3374630 | 0.00064129 |
| Cldn14 | “ | 2.3184480 | 0.00751794 |
| Dyrk1a | dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A | 2.2472669 | 0.00077705 |
| Ckmt2 | sarcomeric mitochondrial creatine kinase | 2.2142101 | 0.00051314 |
| Asb2 | ankyrin repeat and SOCS box-containing protein 2 | 2.1709796 | 0.00039719 |
| Art2b | ADP-ribosyltransferase 2b | 2.1680042 | 0.00124959 |
| LOC498335 | similar to Small inducible cytokine B13 precursor (CXCL13) | 2.1501415 | 0.00012158 |
| Prrx2 | paired related homeobox 2 | 2.1294428 | 0.01452534 |
| LOC364773 | aldo-keto reductase family 1, member C12 | 2.1023343 | 0.00302323 |
| Cdkn2b | cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) | 2.0882944 | 0.00336651 |
| Cd22 | CD22 molecule | 2.0855279 | 0.01215534 |
| Nhlrc2 | NHL repeat containing 2 | 2.0426710 | 0.00054605 |
| Fcrls | Fc receptor-like S, scavenger receptor | 2.0407116 | 0.00627688 |
| Clca3 | chloride channel calcium activated 3 | 2.0188429 | 0.01580260 |
| Dntt | deoxynucleotidyltransferase, terminal | 2.0019106 | 0.00547055 |
| Grap2 | GRB2-related adaptor protein 2 | 1.9900082 | 0.00968363 |
| Thrsp | thyroid hormone responsive protein | 1.9814822 | 0.02740488 |
| Plek2 | pleckstrin 2 | 1.9662998 | 0.00879852 |
| Alox12 | arachidonate 12-lipoxygenase | 1.9121487 | 0.00631083 |
| Tnfsf4 | tumor necrosis factor (ligand) superfamily, member 4 | 1.8804698 | 0.00229007 |
| Mpzl2 | myelin protein zero-like 2 | 1.8783013 | 0.00003750 |
| Prkag3 | protein kinase, AMP-activated, gamma 3 | 1.8643095 | 0.00970172 |
| Nr0b2 | nuclear receptor subfamily 0, group B, member 2 | 1.8348501 | 0.00251892 |
| Traf3ip3 | TRAF3 interacting protein 3 | 1.8326037 | 0.02787730 |
Fig. 2RT-qPCR validation of eighteen deregulated lncRNAs (a) and twelve deregulated mRNAs (b) in the lumbar enlargements of both groups. Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001. Distribution of the various types of DElncRNAs. c Five classes (bidirectional lncRNAs, antisense lncRNAs, sense lncRNAs, intergenic lncRNAs and the other lncRNAs) were analyzed
Fig. 3Pathway analyses of the 176 up-regulated and 102 down-regulated mRNAs with fold changes > 1.5. a The significant pathways of the up-regulated genes in the MT group. b The significant pathways of the down-regulated genes in the MT group. The biological functions of the differentially expressed mRNAs with fold changes > 1.5 are listed. The significant biological processes (c) cellular components (e) and molecular functions (g) of the up-regulated mRNAs. The significant biological processes (d), cellular components (f) and molecular functions (h) of the down-regulated mRNAs
Fig. 4ceRNA analyses indicated the potential lncRNA/miRNA/mRNA interactions. a The potential binding target miRNAs of the verified lncRNAs. The red nodes mean down-regulated lncRNAs, the gray nodes mean up-regulated lncRNAs, the blue squares mean down-regulated miRNAs we are interested in, the green squares mean up-regulated miRNA we are interested in, and the pink nodes mean the other miRNAs and mRNAs. b The lncRNA/miRNA/mRNA networks that we are interested in are displayed. The green nodes represent lncRNAs, the yellow pentagons represent miRNAs and the pink nodes represent mRNAs we forecasted